Company Of The Day: Roche

+34.05%
Upside
41.11
Market
55.11
Trefis
RHHBY: Roche logo
RHHBY
Roche

What?

Healthcare major Roche (OTCMKTS:RHHBY) reported that its Q1 2022 group sales rose 11% year-over-year on a constant currency basis to CHF 16.45 billion (about $17.7 billion).

Why?

Relevant Articles
  1. What’s Happening With Roche (RHHBY) Stock?
  2. What’s Next For Roche Stock?
  3. Should You Buy, Sell, Or Hold Roche Stock At $42?
  4. Roche Stock Has More Upside
  5. Company Of The Day: Roche
  6. Company Of The Day: Roche

Growth was driven by the diagnostics division, which saw robust demand for Covid-19 tests and a recovery in the base business. The pharma division grew by about 6%.

So What?

However, the company sees a slowdown in Covid-19 driven sales growth. For the full year, it expects that total sales could grow in the low-single digits in constant currency terms while guiding for adjusted earnings growth in the low to mid-single-digit range.

See Our Complete Analysis For Roche

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

 Returns Apr 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 RHHBY Return -3% -7% 68%
 S&P 500 Return -6% -10% 91%
 Trefis Multi-Strategy Portfolio -6% -13% 243%

[1] Month-to-date and year-to-date as of 4/26/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates